ArticleACS sensors2025
Real-Time, Light-Activated, and Multiplexed Monitoring of Base Excision Repair in Living Cells Using Chimeric d/l-DNA Molecular Beacons.
Article in ACS sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CHA-mediated split G-quadruplex assembly: a ratiometric AIE strategy for label-free detection of APE1.Analytical and bioanalytical chemistry · 2026Article
- Lock-Open: An AND Logic-Gated, Entropy-Driven DNA Nanowalker for Highly Sensitive Detection of UDG and APE1 Activities in Hepatocellular Carcinoma.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Base excision repair (BER) is a biologically and biomedically important cellular pathway responsible for repairing common DNA lesions. As a central member of the BER pathway, apurinic/apyrimidinic endonuclease 1 (APE1) is important in DNA repair and has been identified as a diagnostic and predictive biomarker for several diseases, motivating the development of analytical methods. However, the current repertoire of APE1 probes, the majority of which are derived from nucleic acids, are poorly suited for use in living cells and organisms, putting many promising biomedical applications of APE1 out of reach. Here, we exploit the bio-orthogonal properties of mirror-image l-DNA, together with a novel chimeric d/l-DNA molecular beacon architecture, to develop a highly versatile probe for intracellular BER, which we apply to the detection of APE1. The chimeric probe is simple to use, biostable, fast, and permits both real-time and light-controlled monitoring of APE1 activity in the nucleus of living cells, making it well suited for diverse intracellular applications. For example, we show that the probe can rapidly distinguish cells based on different APE1 expression levels and can monitor dynamic APE1 activity at single-cell resolution. Moreover, the generality of the probe design allowed for the development of a multiplexed assay for simultaneous imaging of APE1 and DNA glycosylase activities in living cells, which we used to reveal new insights into the efficacy of several prominent APE1 inhibitors. Overall, the chimeric d/l-DNA beacon probe presented in this work will be highly useful for researchers studying BER and provides a versatile toolkit for the development of improved BER-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.